Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2).

Related collections

Author and article information

Journal

Title: New England Journal of Medicine

Abbreviated Title: N Engl J Med

Publisher: New England Journal of Medicine (NEJM/MMS)

ISSN (Print): 0028-4793

ISSN (Electronic): 1533-4406

Publication date Created: August 15 2018

Publication date (Electronic): August 15 2018

Affiliations

[1 ]From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the Department...

Article

DOI: 10.1056/NEJMoa1802905

PubMed ID: 30110579

SO-VID: 85b7b729-f0cb-42ad-8173-e4b8f30da5d6

License:

http://www.nejmgroup.org/legal/terms-of-use.htm

History

Data availability:

Comments

Comment on this article

scite_

Cited by 755

See all cited by

- Version 1